BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pinato DJ, Brown MW, Trousil S, Aboagye EO, Beaumont J, Zhang H, Coley HM, Mauri FA, Sharma R. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. Br J Cancer 2019;120:512-21. [PMID: 30765873 DOI: 10.1038/s41416-018-0373-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F, Audebert S, Dono R, Lozano A, Gregoire D, Hibner U, Allende DS, Apte SS, Maina F. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol 2021;74:893-906. [PMID: 33197513 DOI: 10.1016/j.jhep.2020.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wium M, Ajayi-Smith AF, Paccez JD, Zerbini LF. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Cancers (Basel) 2021;13:1521. [PMID: 33806258 DOI: 10.3390/cancers13071521] [Reference Citation Analysis]
4 Ng PS, Foo K, Sim S, Wang G, Huang C, Tan LH, Poulsen A, Liu B, Tee DHY, Ahmad NHB, Wang S, Ke Z, Lee MA, Kwek ZP, Joy J, Anantharajan J, Baburajendran N, Pendharkar V, Manoharan V, Vuddagiri S, Sangthongpitag K, Hill J, Keller TH, Hung AW. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors. Bioorg Med Chem 2021;49:116437. [PMID: 34600239 DOI: 10.1016/j.bmc.2021.116437] [Reference Citation Analysis]
5 Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem 2021;224:113690. [PMID: 34256124 DOI: 10.1016/j.ejmech.2021.113690] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Sainaghi PP, Bellan M, Nerviani A. Role of the Gas6/TAM System as a Disease Marker and Potential Drug Target. Dis Markers 2021;2021:2854925. [PMID: 33532004 DOI: 10.1155/2021/2854925] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu Y, Liu L, Liu L, Wang T, Guo L, Wang Y, Gao Z, Shu Y. A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors. Cancer Chemother Pharmacol 2020;85:907-15. [PMID: 32266457 DOI: 10.1007/s00280-020-04062-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Batur T, Argundogan A, Keles U, Mutlu Z, Alotaibi H, Senturk S, Ozturk M. AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization. Int J Mol Sci 2021;22:13247. [PMID: 34948046 DOI: 10.3390/ijms222413247] [Reference Citation Analysis]
10 Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open 2020;5:e000714. [PMID: 32847838 DOI: 10.1136/esmoopen-2020-000714] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
11 Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin Ther Targets 2021;25:141-51. [PMID: 33356674 DOI: 10.1080/14728222.2021.1869212] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Horst AK, Tiegs G, Diehl L. Contribution of Macrophage Efferocytosis to Liver Homeostasis and Disease. Front Immunol 2019;10:2670. [PMID: 31798592 DOI: 10.3389/fimmu.2019.02670] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Reference Citation Analysis]
14 Lai Y, Wang K, Hsieh H, Yen W. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma. J Biomed Sci 2022;29. [DOI: 10.1186/s12929-022-00788-0] [Reference Citation Analysis]
15 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
16 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]